Study of Avelumab-M3814 Combinations

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2018
The main purpose of the study is to evaluate a safe, tolerable recommended Phase II dose (RP2D) and/or the maximum tolerated dose (MTD) of M3814 when given in combination with avelumab with and without radiotherapy in participants with selected advanced solid tumors.
Epistemonikos ID: 4f278b477da44de30a8fd6349ece67668c85e024
First added on: May 21, 2024